AI Article Synopsis
- The study aimed to investigate the long-term safety of methylphenidate (MPH), particularly regarding its impact on pubertal maturation and bone age.
- Participants from a two-year observational study were compared across three groups: those on MPH, those not on MPH, and a control group without ADHD.
- Results showed no differences in sexual maturation between medicated and unmedicated ADHD groups, and while there was slight bone maturation acceleration in the medicated group, their predicted adult height remained stable, indicating no long-term safety concerns with MPH.
Article Abstract
Objective: The short-term safety of methylphenidate (MPH) has been widely demonstrated; however the long-term safety is less clear. The aim of this study was to investigate the safety of MPH in relation to pubertal maturation and to explore the monitoring of bone age.
Method: Participants from ADDUCE, a two-year observational longitudinal study with three parallel cohorts (MPH group, no-MPH group, and a non-ADHD control group), were compared with respect to Tanner staging. An Italian subsample of medicated-ADHD was further assessed by the monitoring of bone age.
Results: The medicated and unmedicated ADHD groups did not differ in Tanner stages indicating no higher risk of sexual maturational delay in the MPH-treated patients. The medicated subsample monitored for bone age showed a slight acceleration of the bone maturation after 24 months, however their predicted adult height remained stable.
Conclusion: Our results do not suggest safety concerns on long-term treatment with MPH in relation to pubertal maturation and growth.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/10870547241226726 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!